- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal antibodies therapies for ovarian cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 13, Issue 5, Pages 739-764
Publisher
Informa Healthcare
Online
2013-02-04
DOI
10.1517/14712598.2013.767328
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy
- (2017) K. A. Gelmon et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
- (2017) T. D. Tillmanns et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study.
- (2017) A. J. White et al. JOURNAL OF CLINICAL ONCOLOGY
- Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response (CR) post-first-line chemotherapy (FLCT): Preliminary results of the randomized, double-blind, placebo-controlled, multicenter MIMOSA trial.
- (2017) P. Sabbatini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
- (2017) D. Jelovac et al. JOURNAL OF CLINICAL ONCOLOGY
- AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
- (2017) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Ovarian Cancer, Version 3.2012
- (2017) Robert J. Morgan et al. Journal of the National Comprehensive Cancer Network
- A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
- (2012) S. B. Kaye et al. ANNALS OF ONCOLOGY
- Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls
- (2012) Iván Díaz-Padilla et al. Clinical & Translational Oncology
- Ovarian Cancer
- (2012) JESSICA HUNN et al. CLINICAL OBSTETRICS AND GYNECOLOGY
- Bevacizumab in endometrial cancer treatment
- (2012) Matteo Morotti et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Clinical translation of folate receptor-targeted therapeutics
- (2012) Lesheng Teng et al. Expert Opinion on Drug Delivery
- A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
- (2012) Marcela G. del Carmen et al. GYNECOLOGIC ONCOLOGY
- Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
- (2012) Georgia A. McCann et al. GYNECOLOGIC ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in Renal Diseases
- (2012) Ajay Kher et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapies in Dermatologic Disorders
- (2012) Robyn S. Fallen et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapy in Miscellaneous Medical Disorders Graves Ophthalmopathy, Asthma, and Regional Painful Syndrome
- (2012) Michael Gonzales et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapies in Rheumatologic Disorders
- (2012) Anne V. Miller et al. MEDICAL CLINICS OF NORTH AMERICA
- Immunotherapy in Inflammatory Bowel Disease
- (2012) Jatinder P. Ahluwalia MEDICAL CLINICS OF NORTH AMERICA
- Immune Effects of Trastuzumab
- (2012) Marianna Nuti et al. Journal of Cancer
- Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways
- (2012) Donavon Hiss Journal of Oncology
- New drugs for ovarian cancer
- (2011) K. Bell-McGuinn et al. ANNALS OF ONCOLOGY
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Biomarkers in the development of anti-angiogenic therapies for ovarian cancer
- (2011) Fharat A. Raja et al. CANCER TREATMENT REVIEWS
- Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View
- (2011) Filippo Bellati et al. Clinical & Developmental Immunology
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
- (2011) N. K. Ibrahim et al. CLINICAL CANCER RESEARCH
- Abagovomab for ovarian cancer
- (2011) Jacobus Pfisterer et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
- (2011) Kazuya Kudoh et al. GYNECOLOGIC ONCOLOGY
- Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group
- (2011) K. Baumann et al. GYNECOLOGIC ONCOLOGY
- Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
- (2011) Marion G. Ott et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
- (2010) J-M Lee et al. BRITISH JOURNAL OF CANCER
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
- (2010) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Farletuzumab in epithelial ovarian carcinoma
- (2010) Whitney A Spannuth et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Catumaxomab – trifunctional anti-EpCAM antibody used to treat malignant ascites
- (2010) Carsten Bokemeyer EXPERT OPINION ON BIOLOGICAL THERAPY
- The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab
- (2010) M.P. Smerdel et al. GYNECOLOGIC ONCOLOGY
- Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer
- (2010) Ernest S. Han et al. GYNECOLOGIC ONCOLOGY
- The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer
- (2010) K.D. Steffensen et al. GYNECOLOGIC ONCOLOGY
- Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
- (2010) Jean A. Hurteau et al. GYNECOLOGIC ONCOLOGY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer
- (2010) Maja Patricia Smerdel et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel
- (2010) P. Hoskins et al. JNCI-Journal of the National Cancer Institute
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
- (2009) C Horlock et al. BRITISH JOURNAL OF CANCER
- Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
- (2009) Timothy E. Kute et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2009) L. C. Benavides et al. CLINICAL CANCER RESEARCH
- Use of monoclonal antibodies in the treatment of ovarian cancer
- (2009) Seiji Mabuchi et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Pertuzumab
- (2009) S.P. Langdon et al. DRUGS OF THE FUTURE
- Monoclonal antibody therapies for solid tumors
- (2009) Dimiter V Tassev et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
- (2009) Filippo Bellati et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
- (2009) Michael A. Bookman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
- (2009) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2009) Neil L. Spector et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- (2009) Sharmila Makhija et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
- (2009) Noriyuki Katsumata et al. LANCET
- Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity
- (2009) Y. Nagumo et al. MOLECULAR CANCER RESEARCH
- Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients
- (2009) Eati Basal et al. PLoS One
- Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges
- (2009) Doris R. Siwak et al. Journal of Oncology
- Antiangiogenic drugs in ovarian cancer
- (2008) G C Kumaran et al. BRITISH JOURNAL OF CANCER
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- Approved monoclonal antibodies for cancer therapy
- (2008) Michael Boyiadzis et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Implications of EGFR inhibition in ovarian cancer cell proliferation
- (2008) Shawna L. Bull Phelps et al. GYNECOLOGIC ONCOLOGY
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
- (2008) Jason Konner et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
- (2008) Angeles Alvarez Secord et al. GYNECOLOGIC ONCOLOGY
- Folate receptor alpha as a tumor target in epithelial ovarian cancer
- (2008) Kimberly R. Kalli et al. GYNECOLOGIC ONCOLOGY
- Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
- (2008) Nilofer S. Azad et al. JOURNAL OF CLINICAL ONCOLOGY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer
- (2008) Jonathan S. Berek et al. JOURNAL OF IMMUNOTHERAPY
- The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer
- (2008) Patricia Braly et al. JOURNAL OF IMMUNOTHERAPY
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started